Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
about
Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes.Studying hallucinations within the NIMH RDoC frameworkIdentification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patientsWhy Psychiatric Research Must Abandon Traditional Diagnostic Classification and Adopt a Fully Dimensional Scope: Two Solutions to a Persistent Problem.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Research Domain Criteria: toward future psychiatric nosologies.Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanismToward the future of psychiatric diagnosis: the seven pillars of RDoCModeling treatment-resistant depression.Integrating Children's Mental Health into Primary Care.Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathologyLost in translation. New unexplored avenues for neuropsychopharmacology: epigenetics and microRNAs.The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients.Opioid antagonists in broadly defined behavioral addictions: a narrative review.Attention and the Cholinergic System: Relevance to Schizophrenia.Further evaluation of quantum chemical methods for the prediction of non-specific binding of positron emission tomography tracers.Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder.Translating intermediate phenotypes to psychopathology: the NIMH Research Domain Criteria.The role of fMRI in drug development.
P2860
Q26765884-86EB3E03-97AC-443B-9D99-265F7ACACC98Q30432446-CF066B67-B4E0-4C48-A895-1E64A3A31B27Q30511886-CADE38FB-E426-43DA-BF21-F0E267FE1AEFQ33770132-64C1968E-E6D8-4A83-8272-EAABADD761CAQ33963735-ED6E22C8-4C52-48B3-BE1B-84FF867288D7Q34169978-B37E0DA7-43F0-46A4-A041-B316B05B1F0AQ34476922-19268CAE-B942-4F24-A8FE-05B27188077FQ34657940-1A4EB3CB-5749-40C6-AC8F-B1A7B8E46803Q34721927-06556BEB-43C6-45A6-9E4A-647C303FE347Q35032461-FA13274C-F051-4C84-A90D-53D1A9511E25Q36329378-C2B64044-2CB8-4228-A4ED-5F81608C1BF2Q36998471-DCB77AB8-37BE-4CEA-B94C-6F0D1D0A9A15Q37568528-62B13F24-48F9-42F8-A20D-363D79D7A1DDQ38068561-E8EDF213-DB88-4FB0-BE83-B73570B8BC19Q38170139-F92397F0-13A2-4C20-8D7A-F4838232EDE9Q38707726-64E274DE-89D0-4DAA-B54E-D27523AB6E73Q38897372-82FEDA18-B141-4FDF-87EA-DBB86DC225FFQ44687128-A4CDF06D-380B-4F12-B229-82699CAD638EQ47157142-6DBE1353-CC8A-4DFE-BDE3-944BCD4F0E57Q48459490-BE190268-DC00-462D-B08A-97CA167ECEC7Q49873690-B4060008-A356-425A-9C9F-5BBDF98BF7B4
P2860
Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Challenges and opportunities f ...... the drug hunters' perspective.
@en
Challenges and opportunities f ...... the drug hunters' perspective.
@nl
type
label
Challenges and opportunities f ...... the drug hunters' perspective.
@en
Challenges and opportunities f ...... the drug hunters' perspective.
@nl
prefLabel
Challenges and opportunities f ...... the drug hunters' perspective.
@en
Challenges and opportunities f ...... the drug hunters' perspective.
@nl
P2093
P2860
P1476
Challenges and opportunities f ...... the drug hunters' perspective.
@en
P2093
Chi-Ming Lee
Erik H F Wong
Frank Yocca
Mark A Smith
P2860
P304
P356
10.1017/S1461145710000866
P577
2010-08-18T00:00:00Z